A novel stem cell–based therapy is redefining pain management by harnessing pain-sensing neurons to suppress inflammation and safeguard joint health. Newly released preclinical results highlight SN101, a first-in-class treatment derived from induced pluripotent stem cells (iPSCs), which takes a fundamentally different biological approach to chronic pain compared with conventional therapies.

SN101 consists of mature, iPSC-derived peripheral pain-sensing neurons, known as nociceptors, developed to treat chronic joint pain associated with osteoarthritis. Rather than directly blocking pain signals, the findings suggest the therapy modulates pain pathways through an unconventional biological mechanism.

Figure 1. Fluorescence Image of iPSC-Derived Nociceptors Used in SN101 “Pain Sponge” Therapy

Gabsang Lee, scientific co-founder of SereNeuro and a professor of neurology and neuroscience at Johns Hopkins University, explained that the approach uses high-purity, iPSC-derived nociceptors (SN101) that act as a “sponge” for pain-related factors. When injected, these cells unexpectedly reduce pain while also preventing cartilage breakdown. Figure 1 shows Fluorescence Image of iPSC-Derived Nociceptors Used in SN101 “Pain Sponge” Therapy.

After administration, SN101 neurons sequester pain-associated inflammatory molecules without relaying pain signals to the brain, while also releasing mechanistically validated regenerative factors. This dual action positions SN101 as a potential disease-modifying osteoarthritis drug (DMOAD). The findings were presented by SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid treatments for chronic pain.

A New Approach That Sets It Apart from Conventional Pain Therapies

The findings set SN101 apart from emerging single-target pain therapies, such as Nav1.8 inhibitors, which act by blocking a single signaling pathway. In contrast, SN101 cells express the full complement of canonical pain receptors and ion channels, enabling the therapy to simultaneously modulate multiple pathways to suppress pain and inflammation [1]. The data also distinguish SN101 from current standard treatments, including corticosteroids.

Dr. Daniël Saris, a member of SereNeuro’s Clinical Advisory Board and professor of orthopedics and regenerative medicine at Mayo Clinic, noted that while corticosteroids can offer short-term symptom relief, they are known to accelerate cartilage degradation over time, ultimately worsening disease progression.

In contrast, SN101 promotes a joint environment that preserves tissue integrity and alleviates chronic pain, without carrying the risk of addiction.

References:

1. https://scitechdaily.com/non-opioid-pain-sponge-therapy-stops-cartilage-loss-and-eases-chronic-pain/

Cite this article:

Janani R (2025), Non-Opioid “Pain Sponge” Therapy Prevents Cartilage Loss and Relieves Chronic Pain, AnaTechMaz, pp. 640